CHARLES RIVER LABORATORIES (CRL)
US1598641074 - Common Stock
ChartMill assigns a Buy % Consensus number of 66% to CRL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 222.25. This target is 13.53% above the current price.
CRL was analyzed by 25 analysts. The buy percentage consensus is at 66. So analysts seem to be have mildly positive about CRL.
In the last month the buy percentage fell by 6 points. So the trust of analysts is decreasing.
CRL was analyzed by 25 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-11 | TD Cowen | Maintains | Hold -> Hold |
| 2024-11-07 | UBS | Maintains | Buy -> Buy |
| 2024-11-07 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2024-10-23 | CLSA | Initiate | Underperform |
| 2024-10-14 | Redburn Atlantic | Initiate | Sell |
| 2024-10-07 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2024-10-02 | B of A Securities | Downgrade | Buy -> Neutral |
| 2024-10-01 | Citigroup | Downgrade | Neutral -> Sell |
| 2024-09-20 | Baird | Maintains | Neutral -> Neutral |
| 2024-08-12 | TD Cowen | Maintains | Hold -> Hold |
| 2024-08-08 | UBS | Maintains | Buy -> Buy |
| 2024-08-08 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-08-08 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-08-08 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2024-08-08 | Baird | Downgrade | Outperform -> Neutral |
| 2024-08-08 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-07-10 | Baird | Maintains | Outperform -> Outperform |
| 2024-06-28 | Argus Research | Downgrade | Buy -> Hold |
| 2024-06-28 | Barclays | Initiate | Equal-Weight |
| 2024-06-07 | Mizuho | Initiate | Neutral |
| 2024-06-06 | Goldman Sachs | Initiate | Buy |
| 2024-05-13 | TD Cowen | Maintains | Hold -> Hold |
| 2024-05-10 | Baird | Maintains | Outperform -> Outperform |
| 2024-03-18 | Argus Research | Maintains | Buy -> Buy |
| 2024-02-15 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-02-15 | UBS | Maintains | Buy -> Buy |
| 2024-02-15 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-02-15 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-02-15 | Baird | Maintains | Outperform -> Outperform |
| 2024-02-15 | Citigroup | Maintains | Neutral -> Neutral |